Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2020
Event: Entry into a Material Definitive Agreement for a public offering of common stock.
Key Financial Metrics
- Offering Size: 32,260,000 shares of Common Stock.
- Offering Price: $1.55 per share.
- Expected Net Proceeds: Approximately $46.5 million (after underwriting discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 4,839,000 additional shares.
- Cash Position (Preliminary): Approximately $28.6 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2019.
- Revenue, Profit, Margins, Debt: The filing text does not provide specific values for revenue, profit, margins, or debt levels.
Material Changes
This filing reports a material change in the Company's capital structure through the execution of an underwriting agreement with Piper Sandler & Co. The transaction is expected to significantly increase the Company's liquidity upon closing, which is anticipated on or about January 14, 2020.
Guidance, Outlook, and Risks
- Outlook: The Company intends to use the proceeds to fund its operations and strategic initiatives, though specific allocation details are not provided in this text.
- Risks and Contingencies:
- The closing of the Offering is subject to customary conditions, which may not be satisfied in a timely manner or at all.
- The reported cash position of $28.6 million is preliminary, unaudited, and subject to change upon completion of the audit for the year ended December 31, 2019.
- Forward-looking statements regarding the Offering involve risks detailed in the Company's Form 10-K and prospectus supplements.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $46.5 million figure is an estimate.
- Confirm the final audited cash and cash equivalents balance for the year ended December 31, 2019, as the $28.6 million figure is preliminary.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, indemnification obligations, and termination provisions.
- Check for the exercise of the 30-day over-allotment option by the underwriters.